- Home
- WHF vs CNTB Comparison
WHF vs CNTB Comparison
Compare WHF & CNTB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | WHF | CNTB |
|---|---|---|
| Founded | 2011 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 152.1M | 135.7M |
| IPO Year | 2012 | 2020 |
Fundamental Metrics
Financial Performance| Metric | WHF | CNTB |
|---|---|---|
| Price | $7.05 | $2.42 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | $7.75 | ★ $8.67 |
| AVG Volume (30 Days) | 46.5K | ★ 359.3K |
| Earning Date | 05-07-2026 | 08-13-2026 |
| Dividend Yield | ★ 13.67% | N/A |
| EPS Growth | ★ 31.91 | N/A |
| EPS | ★ 0.44 | N/A |
| Revenue | N/A | ★ $64,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $15.98 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $6.07 | $1.23 |
| 52 Week High | $8.97 | $3.82 |
Technical Indicators
Market Signals| Indicator | WHF | CNTB |
|---|---|---|
| Relative Strength Index (RSI) | 56.99 | 53.93 |
| Support Level | $6.80 | $2.27 |
| Resistance Level | $7.17 | $2.69 |
| Average True Range (ATR) | 0.17 | 0.16 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 64.94 | 50.94 |
Price Performance
Historical ComparisonAbout WHF WhiteHorse Finance Inc.
WhiteHorse Finance Inc is a non-diversified, closed-end management investment company. It makes debt investments in privately held; small-cap companies located in United States. Its investment objective is to generate risk-adjusted returns by originating and investing in senior secured loans, including first lien and second lien facilities, to performing lower middle market companies across a range of industries.
About CNTB Connect Biopharma Holdings Limited
Connect Biopharma Holdings Ltd is a clinical-stage biopharmaceutical company dedicated to transforming care for asthma and chronic obstructive pulmonary disease (COPD). The company is advancing rademikibart, a next-generation antibody designed to target interleukin-4-receptor alpha. It is currently conducting clinical studies of rademikibart for the treatment of acute exacerbations of asthma and COPD. The company operates in one operating segment: treatment of respiratory diseases.